Can-Fite BioPharma Ltd. (CANF.TA)
ILA 1.8
(0.0%)
ILA 1.8
(0.0%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -8.44 Million | -10.8 Million | -9.85 Million | -12.06 Million | -10.83 Million | -4.15 Million |
| Net Income | -7.63 Million | -10.17 Million | -12.61 Million | -14.44 Million | -12.62 Million | -6.57 Million |
| Depreciation & Amortization | 15 Thousand | 14 Thousand | 14 Thousand | 12 Thousand | 14 Thousand | 14 Thousand |
| Deferred income taxes | 83 Thousand | - | -94 Thousand | 11 Thousand | 212 Thousand | - |
| Stock-based compensation | 261 Thousand | 263 Thousand | 466 Thousand | 355 Thousand | 385 Thousand | 535 Thousand |
| Change in working capital | -943 Thousand | -1.3 Million | 2.48 Million | 2 Million | 1.18 Million | 1.13 Million |
| Other non-cash items | -222 Thousand | 396 Thousand | -46 Thousand | 1000.00 | -5000.00 | 733 Thousand |
| Investing Cash Flow | 498 Thousand | 9.5 Million | -14.51 Million | -26 Thousand | -253 Thousand | -33 Thousand |
| Investments in PPE | -2000.00 | -9000.00 | -11 Thousand | -26 Thousand | -3000.00 | -33 Thousand |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | -14.5 Million | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | 500 Thousand | 9.51 Million | -14.5 Million | - | -250 Thousand | - |
| Financing Cash Flow | 9.14 Million | - | 20.45 Million | 17.68 Million | 10.16 Million | 4.38 Million |
| Debt repayment | - | - | - | - | -34 Thousand | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | 9.14 Million | - | 20.45 Million | 17.68 Million | 10.16 Million | 4.38 Million |
| Other Financing Activities | 9.14 Million | - | 20.45 Million | 17.68 Million | 34 Thousand | 4.38 Million |
| Accounts receivables | - | - | - | 2.72 Million | 270 Thousand | -853 Thousand |
| Accounts payables | -469 Thousand | -58 Thousand | 393 Thousand | -1.59 Million | 1.08 Million | 644 Thousand |
| Inventory | - | - | - | 1.27 Million | -316 Thousand | 125 Thousand |
| Other working capital | -474 Thousand | -1.24 Million | 2.09 Million | -401 Thousand | 146 Thousand | 1.21 Million |
| Cash at beginning of period | 2.97 Million | 4.39 Million | 8.26 Million | 2.69 Million | 3.61 Million | 3.5 Million |
| Cash at end of period | 4.27 Million | 2.97 Million | 4.39 Million | 8.26 Million | 2.69 Million | 3.61 Million |
| Capital Expenditure | -2000.00 | -9000.00 | -11 Thousand | -26 Thousand | -3000.00 | -33 Thousand |
| Effect of forex changes on cash | 98 Thousand | -113 Thousand | 34 Thousand | -23 Thousand | 2000.00 | -89 Thousand |
| Net cash flow / Change in cash | 1.3 Million | -1.41 Million | -3.87 Million | 5.57 Million | -918 Thousand | 110 Thousand |
| Free Cash Flow | -8.44 Million | -10.81 Million | -9.86 Million | -12.08 Million | -10.83 Million | -4.18 Million |
| Breakdown | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 | 2023 Q1 | 2022 FY |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -1.65 Million | -7.63 Million | -1.76 Million | -1.67 Million | -2.55 Million | -10.17 Million |
| Depreciation & Amortization | - | 15 Thousand | - | - | - | 14 Thousand |
| Deferred income taxes | - | 83 Thousand | - | - | - | - |
| Stock-based compensation | 261 Thousand | 261 Thousand | -95 Thousand | 95 Thousand | - | 263 Thousand |
| Change in working capital | - | -943 Thousand | - | - | - | -1.3 Million |
| Other non-cash items | 1.39 Million | -222 Thousand | 1.85 Million | 1.57 Million | 2.55 Million | 396 Thousand |
| Investing Cash Flow | - | 498 Thousand | - | - | - | 9.5 Million |
| Investments in PPE | - | -2000.00 | - | - | - | -9000.00 |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | - | 500 Thousand | - | - | - | 9.51 Million |
| Financing Cash Flow | - | 9.14 Million | - | - | - | - |
| Debt repayment | - | - | - | - | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | 9.14 Million | - | - | - | - |
| Other Financing Activities | - | 9.14 Million | - | - | - | - |
| Accounts receivables | - | - | - | - | - | - |
| Accounts payables | - | -469 Thousand | - | - | - | -58 Thousand |
| Inventory | - | - | - | - | - | - |
| Other working capital | - | -474 Thousand | - | - | - | -1.24 Million |
| Cash at beginning of period | - | 2.97 Million | - | - | - | 4.39 Million |
| Cash at end of period | - | 4.27 Million | -95 Thousand | 95 Thousand | - | 2.97 Million |
| Capital Expenditure | - | -2000.00 | - | - | - | -9000.00 |
| Effect of forex changes on cash | - | 98 Thousand | - | - | - | -113 Thousand |
| Net cash flow / Change in cash | - | 1.3 Million | -95 Thousand | 95 Thousand | - | -1.41 Million |
| Free Cash Flow | - | -8.44 Million | -95 Thousand | 95 Thousand | - | -10.81 Million |
OMIP
PRU
VNWTF
2694
5984
PFD